The Journal of reproductive medicine · 2005
Preliminary evaluation of a cervical self-sampling device with liquid-based cytology and multiparameter molecular testing.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Knesel Bradley W, Dry Joel C, Wald-Scott Coridalia, Aftab Asma
Аннотация
OBJECTIVE: To compare the collection of a liquid-based cell sample using a cervical self-sampling device and traditional sampling using cytologic and molecular-based tests.
STUDY DESIGN: This study evaluated the sampling efficiency of the Fournier Cervical Self-Sampling Device (BPG, LLC, Miami, Florida) with regard to overall cell volume of the sample, cytologic diagnoses Path, TriPath Imaging, Burlington, North Carolina) and molecular-based tests for Chlamydia, Gonorrhoeae and human papillomavirus (Hybrid Capture 2, Digene Corp., Gaithersburg, Maryland). Paired samples were blinded and prepared using the SurePath method.
RESULTS: The self-collected samples showed an overall increase in cellularity when compared to the cellularity of samples obtained from traditional sampling. Cytologic results were comparable for the 2 sampling methods. The self-sampling device showed greater sensitivity with regard to molecular-based human papillomavirus testing.
CONCLUSION: The Fournier Device shows promise in the area of cytology and molecular diagnostics. The ability to perform cytology and molecular-based assays using a single sample obtained directly by the patient can lower the costs of screening and provide an efficient method of screening women in resource-poor countries or when cultural barriers exist to the use of traditional sampling methods.
STUDY DESIGN: This study evaluated the sampling efficiency of the Fournier Cervical Self-Sampling Device (BPG, LLC, Miami, Florida) with regard to overall cell volume of the sample, cytologic diagnoses Path, TriPath Imaging, Burlington, North Carolina) and molecular-based tests for Chlamydia, Gonorrhoeae and human papillomavirus (Hybrid Capture 2, Digene Corp., Gaithersburg, Maryland). Paired samples were blinded and prepared using the SurePath method.
RESULTS: The self-collected samples showed an overall increase in cellularity when compared to the cellularity of samples obtained from traditional sampling. Cytologic results were comparable for the 2 sampling methods. The self-sampling device showed greater sensitivity with regard to molecular-based human papillomavirus testing.
CONCLUSION: The Fournier Device shows promise in the area of cytology and molecular diagnostics. The ability to perform cytology and molecular-based assays using a single sample obtained directly by the patient can lower the costs of screening and provide an efficient method of screening women in resource-poor countries or when cultural barriers exist to the use of traditional sampling methods.